Trial Profile
A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Who Are Nucleoside-Naive.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Entecavir (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 15 Oct 2012 Primary endpoint 'Virological-response-rate' has been met, according to a Bristol-Myers Squibb media release.
- 15 Oct 2012 Primary endpoint 'Viral-load' has been met, according to a Bristol-Myers Squibb media release.
- 15 Oct 2012 Efficacy and pharmacokinetic results were reported in a Bristol-Myers Squibb media release.